Current Report Filing (8-k)
19 12월 2017 - 1:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 18, 2017 (December 13, 2017)
LUCKYCOM
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-187874
|
|
46-1660653
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
11767
Katy Freeway, Suite 830, Houston, Texas
|
|
77079
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, include area code
281-668-8266
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K fi ling is intended to simultaneously satisfy the fi ling obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
2.01
|
Completion
of Acquisition or Disposition of Assets.
|
On
December 13, 2017, Mr. Kingrich Lee executed a Sold Note (the “
Sold Note
”) and Instrument of Transfer (the
“
Instrument of Transfer
”) on behalf of Luckycom Pharmaceuticals Inc. (the “
Company
”), pursuant
to which the Company would sell to Ms. Lijian Li 10,000 shares of stock of the Company’s wholly-owned Hong Kong subsidiary,
Luckycom Limited at a purchase price of HK $1 (approximately US $0.13) per share aggregating to HK $10,000 (approximately US $1,281)
. On the same date, the transaction was consummated with the payment of stamp duty to the Hong Kong tax department.
The
foregoing description of the Sold Note and Instrument of Transfer does not purport to be complete and is qualified in its entirety
by the Sold Note and Instrument of Transfer, and Copies of the Sold Note and Instrument of Transfer are attached to this Current
Report on Form 8-K as Exhibit 2.1 and 2.2 which are incorporated herein by reference.
Item
9.01
|
Financial
Statements and Exhibits.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
LUCKYCOM
PHARMACEUTICALS INC.
|
|
|
Date:
December 18, 2017
|
|
/s/
Kingrich Lee
|
|
Name:
|
Kingrich
Lee
|
|
Title:
|
Chief
Executive Officer and Chief Financial Officer
|
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024